

18 December 2009

Company Announcements ASX Limited Exchange Centre 20 Bridge Street SYDNEY NSW 2000

## QRxPharma Limited (QRxPharma) - Notice of Subscriptions under Rights Issue

We refer to the rights issue announced by QRxPharma on 16 November 2009 (**Rights Issue**) and the Rights Issue booklet lodged with the ASX on 16 November 2009 (**Rights Issue Booklet**).

We advise that QRxPharma has now completed its Rights Issue to Eligible Shareholders (as defined in the Rights Issue Booklet) which closed for acceptances at 5pm on Tuesday 15 December 2009. This follows completion of the institutional placement announced on 16 November 2009 which raised \$8 million before expenses.

QRxPharma received valid acceptances in relation to 11,189,584 new QRxPharma shares, representing approximately 65.8% of the total number of new QRxPharma shares offered to Eligible Shareholders under the Rights Issue.

As a result, the shortfall in the Rights Issue is approximately 34.2% representing 5,810,416 ordinary shortfall shares.

As the Rights Issue is fully underwritten, new shares not applied for under the Rights Issue will be issued to RBS Morgans Corporate Limited (**RBS Morgans**) at an offer price of \$0.80 per share in accordance with the underwriting agreement between QRxPharma and RBS Morgans. RBS Morgans has in turn entered into sub-underwriting agreements for the total number of ordinary shortfall shares.

On 21 December 2009, the new shares under the Rights Issue will be allotted and shareholder statements will be despatched. These new shares are expected to commence trading on the ASX on 22 December 2009. The shortfall shares will be allotted on 23 December 2009.

Please contact me if you have any queries.

Yours sincerely

Chris Campbell
Company Secretary

C. J. Campbell

**QRxPharma** Limited